Diversification of host bile acids by members of the gut microbiota

References

• Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev. 2005;29(4):625–651. doi:10.1016/j.femsre.2004.09.003.
   Google Scholar
• Setchell KD, Lawson AM, Tanida N, Sjovall J. General methods for the analysis of metabolic profiles of bile acids and related compounds in feces. J Lipid Res. 1983;24:1085–1100.
   Google Scholar
• Ridlon JM, Bajaj JS. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharmaceutica Sinica B. 2015;5(2):99–105. doi:10.1016/j.apsb.2015.01.006.
   Google Scholar
• Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med. 2015;21:702–714. doi:10.1016/j.molmed.2015.09.001.
   Google Scholar
• Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap–bile acids in metabolic control. Nat Rev Endocrinol. 2014;10(8):488–498. doi:10.1038/nrendo.2014.60.
   Google Scholar
• Nie YF, Hu J, Yan XH. Cross-talk between bile acids and intestinal microbiota in host metabolism and health. J Zhejiang Univ Sci B. 2015;16(6):436–446. doi:10.1631/jzus.B1400327.
   Google Scholar
• Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and clostridium difficile. Annu Rev Microbiol. 2015;69:445–461. doi:10.1146/annurev-micro-091014-104115.
   Google Scholar
• Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M-A, Quervain E, Thomas G, Barbu V, Humbert L, Despras G, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–539. doi:10.1136/gutjnl-2012-302578.
   Google Scholar
• Shen A. A gut odyssey: the impact of the microbiota on clostridium difficile spore formation and germination. PLoS Pathog. 2015;11:e1005157. doi:10.1371/journal.ppat.1005157.
   Google Scholar
• Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 2017;8(1785). doi:10.1038/s41467-017-01682-2.
   Google Scholar
• Wahlstrom A, Kovatcheva-Datchary P, Stahlman M, Backhed F, Marschall HU. Crosstalk between bile acids and gut microbiota and its impact on farnesoid X receptor signalling. Dig Dis. 2017;35(3):246–250. doi:10.1159/000450982.
   Google Scholar
• Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol. 2017;101(1):47–64. doi:10.1007/s00253-016-8006-6.
   Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(241–259). doi:10.1194/jlr.R500013-JLR200.
   Google Scholar
• Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 2013;4(5):382–387. doi:10.4161/gmic.25723.
   Google Scholar
• Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72(1):137–174. doi:10.1146/annurev.biochem.72.121801.161712.
   Google Scholar
• Hofmann AF, Hagey LR, Krasowski MD. Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res. 2010;51(2):226–246. doi:10.1194/jlr.R000042.
   Google Scholar
• Hofmann AF. The enterohepatic circulation of bile acids in mammals: form and functions. Front Biosci. 2009;14:2584–2598. doi:10.2741/3399.
   Google Scholar
• Zhang Y, Limaye PB, Renaud HJ, Klaassen CD. Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice. Toxicol Appl Pharmacol. 2014;277(2):138–145. doi:10.1016/j.taap.2014.03.009.
   Google Scholar
• Hofmann AF, Mysels KJ. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res. 1992;33:617–626.
   Google Scholar
• Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology. 2009;49(5):1403–1418. doi:10.1002/hep.22789.
   Google Scholar
• Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65(7–8):1220–1236. doi:10.1007/s00018-008-7568-6.
   Google Scholar
• Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol Sci. 1999;14:24–29.
   Google Scholar
• Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50(10):1955–1966. doi:10.1194/jlr.R900010-JLR200.
   Google Scholar
• Chiang JY. Bile acid metabolism and signaling. Compr Physiol. 2013;3(1191–1212). doi:10.1002/cphy.c120023.
   Google Scholar
• Wagner M, Trauner M. Recent advances in understanding and managing cholestasis. F1000Research. 2016;5:705. doi:10.12688/f1000research.8012.1.
   Google Scholar
• Stellaard F, Sackmann M, Sauerbruch T, Paumgartner G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res. 1984;25:1313–1319.
   Google Scholar
• Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis. 2015;33(3):327–331. doi:10.1159/000371670.
   Google Scholar
• Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci. 2006;31(10):572–580. doi:10.1016/j.tibs.2006.08.002.
   Google Scholar
• Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014;7(12–18). doi:10.1016/j.celrep.2014.02.032.
   Google Scholar
• Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol. 2013;14(7):676–684. doi:10.1038/ni.2640.
   Google Scholar
• Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103:3920–3925. doi:10.1073/pnas.0509592103.
   Google Scholar
• Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11(1):55–67. doi:10.1038/nrgastro.2013.151.
   Google Scholar
• de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17(657–669). doi:10.1016/j.cmet.2013.03.013.
   Google Scholar
• Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: solving the puzzle with nuclear receptors. Trends Mol Med. 2011;17(10):564–572. doi:10.1016/j.molmed.2011.05.010.
   Google Scholar
• Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31(1):107–133. doi:10.1146/annurev.mi.31.100177.000543.
   Google Scholar
• Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. doi:10.1371/journal.pbio.1002533.
   Google Scholar
• Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780–13785. doi:10.1073/pnas.0706625104.
   Google Scholar
• Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638. doi:10.1126/science.1110591.
   Google Scholar
• Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–848. doi:10.1016/j.cell.2006.02.017.
   Google Scholar
• Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(59–65). doi:10.1038/nature08821.
   Google Scholar
• O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(688–693). doi:10.1038/sj.embor.7400731.
   Google Scholar
• Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A. 2008;105:13580–13585. doi:10.1073/pnas.0804437105.
   Google Scholar
• Bustos AY, de Valdez F, Fadda G, Taranto MP. New insights into bacterial bile resistance mechanisms: the role of bile salt hydrolase and its impact on human health. Food Res Int. 2018;112(250–262):250–262. doi:10.1016/j.foodres.2018.06.035.
   Google Scholar
• Kleerebezem M, Boekhorst J, van Kranenburg R, Molenaar D, Kuipers OP, Leer R, Tarchini R, Peters SA, Sandbrink HM, Fiers MWEJ, et al. Complete genome sequence of Lactobacillus plantarum WCFS1. Proc Natl Acad Sci U S A. 2003;100:1990–1995. doi:10.1073/pnas.0337704100.
   Google Scholar
• Pridmore RD, Berger B, Desiere F, Vilanova D, Barretto C, Pittet A-C, Zwahlen M-C, Rouvet M, Altermann E, Barrangou R, et al. The genome sequence of the probiotic intestinal bacterium Lactobacillus johnsonii NCC 533. Proc Natl Acad Sci U S A. 2004;101:2512–2517. doi:10.1073/pnas.0307327101.
   Google Scholar
• O’Flaherty S, Briner Crawley A, Theriot CM, Barrangou R. The lactobacillus bile salt hydrolase repertoire reveals niche-specific adaptation. mSphere. 2018:3. doi:10.1128/mSphere.00140-18.
   Google Scholar
• De Smet I, Van Hoorde L, De Saeyer N, Vande Woestyne M, Verstraete W. In vitro study of Bile Salt Hydrolase (BSH) activity of BSH Isogenic Lactobacillus plantarum 80 strains and estimation of cholesterol lowering through enhanced BSH activity. 2009. doi:10.3109/08910609409141371.
   Google Scholar
• Chikai T, Nakao H, Uchida K. Deconjugation of bile acids by human intestinal bacteria implanted in germ-free rats. Lipids. 1987;22:669–671. doi:10.1007/bf02533948.
   Google Scholar
• Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat Chem Biol. 2015;11(9):685–690. doi:10.1038/nchembio.1864.
   Google Scholar
• Ridlon JM, Kang D-J, Hylemon PB, Bajaj JS. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. Dig Dis. 2015;33(3):338–345. doi:10.1159/000371678.
   Google Scholar
• Wells JE, Williams KB, Whitehead TR, Heuman DM, Hylemon PB. Development and application of a polymerase chain reaction assay for the detection and enumeration of bile acid 7alpha-dehydroxylating bacteria in human feces. Clin Chim Acta. 2003;331:127–134. doi:10.1016/s0009-8981(03)00115-3.
   Google Scholar
• Kitahara M, Takamine F, Imamura T, Benno Y. Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7alpha-dehydroxylating activity. Int J Syst Evol Microbiol. 2001;51:39–44. doi:10.1099/00207713-51-1-39.
   Google Scholar
• Kitahara M, Takamine F, Imamura T, Benno Y. Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7alpha-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov., isolated from human faeces. Int J Syst Evol Microbiol. 2000;50 Pt 3:971–978. doi:10.1099/00207713-50-3-971.
   Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB. Isolation and characterization of a bile acid inducible 7alpha-dehydroxylating operon in Clostridium hylemonae TN271. Anaerobe. 2010;16:137–146. doi:10.1016/j.anaerobe.2009.05.004.
   Google Scholar
• Macdonald IA, White BA, Hylemon PB. Separation of 7 alpha- and 7 beta-hydroxysteroid dehydrogenase activities from Clostridium absonum ATCC# 27555 and cellular response of this organism to bile acid inducers. J Lipid Res. 1983;24:1119–1126.
   Google Scholar
• Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517:205–208. doi:10.1038/nature13828.
   Google Scholar
• Dawson JA, Mallonee DH, Bjorkhem I, Hylemon PB. Expression and characterization of a C24 bile acid 7 alpha-dehydratase from Eubacterium sp. strain VPI 12708 in Escherichia coli. J Lipid Res. 1996;37:1258–1267.
   Google Scholar
• Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30(3):332–338. doi:10.1097/MOG.0000000000000057.
   Google Scholar
• Doerner KC, Takamine F, LaVoie CP, Mallonee DH, Hylemon PB. Assessment of fecal bacteria with bile acid 7 alpha-dehydroxylating activity for the presence of bai-like genes. Appl Environ Microbiol. 1997;63:1185–1188.
   Google Scholar
• Wang DQ, Carey MC. Therapeutic uses of animal biles in traditional Chinese medicine: an ethnopharmacological, biophysical chemical and medicinal review. World J Gastroenterol. 2014;20(9952–9975). doi:10.3748/wjg.v20.i29.9952.
   Google Scholar
• Lee JY, Arai H, Nakamura Y, Fukiya S, Wada M, Yokota A. Contribution of the 7β-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic acid formation in the human colon. J Lipid Res. 2013;54:3062–3069. doi:10.1194/jlr.M039834.
   Google Scholar
• Zheng -M-M, Wang R-F, Li C-X, Xu J-H. Two-step enzymatic synthesis of ursodeoxycholic acid with a new 7β-hydroxysteroid dehydrogenase from Ruminococcus torques. Process Biochem. 2015;50:598–604. doi:10.1016/j.procbio.2014.12.026.
   Google Scholar
• Mallonee DH, Hylemon PB. Sequencing and expression of a gene encoding a bile acid transporter from Eubacterium sp. strain VPI 12708. J Bacteriol. 1996;178:7053–7058. doi:10.1128/jb.178.24.7053-7058.1996.
   Google Scholar
• Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190:2505–2512. doi:10.1128/JB.01765-07.
   Google Scholar
• Theriot CM, Koenigsknecht MJ, Carlson PE Jr, Hatton GE, Nelson AM, Li B, Huffnagle GB, Li J, Young VB. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5:3114. doi:10.1038/ncomms4114.
   Google Scholar
• Barrasa JI, Olmo N, Lizarbe MA, Turnay J. Bile acids in the colon, from healthy to cytotoxic molecules. Toxicol In Vitro. 2013;27(2):964–977. doi:10.1016/j.tiv.2012.12.020.
   Google Scholar
• Ward JBJ, Lajczak NK, Kelly OB, O'Dwyer AM, Giddam AK, Ní Gabhann J, Franco P, Tambuwala MM, Jefferies CA, Keely S, et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. American journal of physiology. Gastrointestinal Liver Physiol. 2017;ajpgi.00256.02016. doi:10.1152/ajpgi.00256.2016.
   Google Scholar
• Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall H-U, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225–235. doi:10.1016/j.cmet.2013.01.003.
   Google Scholar
• Jones ML, Tomaro-Duchesneau C, Prakash S. The gut microbiome, probiotics, bile acids axis, and human health. Trends Microbiol. 2014;22(6):306–308. doi:10.1016/j.tim.2014.04.010.
   Google Scholar
• Zhao Y, Wu J, Li JV, Zhou N-Y, Tang H, Wang Y. Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res. 2013;12(6):2987–2999. doi:10.1021/pr400263n.
   Google Scholar
• Samuel P, Holtzman CM, Meilman E, Sekowski I. Effect of neomycin and other antibiotics on serum cholesterol levels and on 7alpha-dehydroxylation of bile acids by the fecal bacterial flora in man. Circ Res. 1973;33:393–402. doi:10.1161/01.res.33.4.393.
   Google Scholar
• Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949–955. doi:10.1016/j.jhep.2013.01.003.
   Google Scholar
• Devkota S, Chang EB. Interactions between diet, bile acid metabolism, gut microbiota, and inflammatory bowel diseases. Dig Dis. 2015;33(3):351–356. doi:10.1159/000371687.
   Google Scholar
• Jones ML, Martoni CJ, Prakash S. Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut. 2013;62:654–655. doi:10.1136/gutjnl-2012-303867.
   Google Scholar
• Foley MH, O’Flaherty S, Barrangou R, Theriot CM. Bile salt hydrolases: gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract. PLoS Pathog. 2019;15(3):e1007581. doi:10.1371/journal.ppat.1007581.
   Google Scholar
• Reeves AE, Theriot CM, Bergin IL, Huffnagle GB, Schloss PD, Young VB. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes. 2014;2:145–158. doi:10.4161/gmic.2.3.16333.
   Google Scholar
• Watanabe M, Fukiya S, Yokota A. Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents. J Lipid Res. 2017;58(6):1143–1152. doi:10.1194/jlr.M075143.
   Google Scholar
• Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183(6251–6261). doi:10.4049/jimmunol.0803978.
   Google Scholar
• Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S, Ryffel B. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 2011;6(10):e25637. doi:10.1371/journal.pone.0025637.
   Google Scholar
• Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011;141(5):1773–1781. doi:10.1053/j.gastro.2011.07.046.
   Google Scholar
• Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306:G310–319. doi:10.1152/ajpgi.00282.2013.
   Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415. doi:10.1056/NEJMoa1205037.
   Google Scholar
• Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol. 2010;192:4983–4990. doi:10.1128/jb.00610-10.
   Google Scholar
• Sorg JA, Sonenshein AL. Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol. 2009;191:1115–1117. doi:10.1128/jb.01260-08.
   Google Scholar
• Weingarden AR, Chen C, Zhang N, Graiziger CT, Dosa PI, Steer CJ, Shaughnessy MK, Johnson JR, Sadowsky MJ, Khoruts A.. Ursodeoxycholic acid inhibits clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol. 2015. doi:10.1097/mcg.0000000000000427.
   Google Scholar
• Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res. 2014;55(1553–1595). doi:10.1194/jlr.R049437.
   Google Scholar
• Hagey LR, Crombie DL, Espinosa E, Carey MC, Igimi H, Hofmann AF. Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores. J Lipid Res. 1993;34:1911–1917.
   Google Scholar
• Takamine F, Imamura T. 7 beta-dehydroxylation of 3,7-dihydroxy bile acids by a Eubacterium species strain C-25 and stimulation of 7 beta-dehydroxylation by Bacteroides distasonis strain K-5. Microbiol Immunol. 1985;29:1247–1252. doi:10.1111/j.1348-0421.1985.tb00915.x.
   Google Scholar
• White BA, Fricke RJ, Hylemon PB. 7 beta-Dehydroxylation of ursodeoxycholic acid by whole cells and cell extracts of the intestinal anaerobic bacterium, Eubacterium species V.P.I. 12708. J Lipid Res. 1982;23:145–153.
   Google Scholar
• Lepercq P, Hermier D, David O, Michelin R, Gibard C, Beguet F, Relano P, Cayuela C, Juste C. Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br J Nutr. 2005;93:457–469. doi:10.1079/bjn20041386.
   Google Scholar
• Hirano S, Masuda N. Epimerization of the 7-hydroxy group of bile acids by the combination of two kinds of microorganisms with 7 alpha-and 7 beta-hydroxysteroid dehydrogenase activity, respectively. J Lipid Res. 1981;22:1060–1068.
   Google Scholar
• Hirano S, Masuda N. Characterization of NADP-dependent 7 beta-hydroxysteroid dehydrogenases from Peptostreptococcus productus and Eubacterium aerofaciens. Appl Environ Microbiol. 1982;43:1057–1063.
   Google Scholar
• Masuda N, Oda H, Tanaka H. Purification and characterization of NADP-dependent 7β-hydroxysteroid dehydrogenase from Peptostreptococcus productus strain b-52. Biochim Biophys Acta, Gen Subj. 1983;755:65–69. doi:10.1016/0304-4165(83)90273-8.
   Google Scholar
• Taiko A, Teruaki A, KOBASHI K. Purification and characterization of 7β-hydroxysteroid dehydrogenase from ruminococus sp. of human intestine. J Biochem. 1987;102:613–619. doi:10.1093/oxfordjournals.jbchem.a122095.
   Google Scholar
• Liu L, Aigner A, Schmid RD. Identification, cloning, heterologous expression, and characterization of a NADPH-dependent 7β-hydroxysteroid dehydrogenase from collinsella aerofaciens. Appl Microbiol Biotechnol. 2011;90:127–135. doi:10.1007/s00253-010-3052-y.
   Google Scholar
• Macdonald IA, Hutchison DM, Forrest TP. Formation of urso-and ursodeoxy-cholic acids from primary bile acids by. Clostridium Absonum. J Lipid Res. 1981;22:458–466.
   Google Scholar
• Macdonald IA, Roach PD. Bile salt induction of 7α-and 7β-hydroxysteroid dehydrogenases in Clostridium absonum. Biochim Biophys Acta, Lipids Lipid Metab. 1981;665:262–269. doi:10.1016/0005-2760(81)90011-4.
   Google Scholar
• Sutherland JD, Macdonald IA. The metabolism of primary, 7-oxo, and 7 beta-hydroxy bile acids by Clostridium absonum. J Lipid Res. 1982;23:726–732.
   Google Scholar
• Alnouti Y, Csanaky IL, Klaassen CD. Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;873(2):209–217. doi:10.1016/j.jchromb.2008.08.018.
   Google Scholar
• Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4523–4530. doi:10.1073/pnas.1006734107.
   Google Scholar
• Rudling M, Bonde Y. Stimulation of apical sodium-dependent bile acid transporter expands the bile acid pool and generates bile acids with positive feedback properties. Dig Dis. 2015;33(3):376–381. doi:10.1159/000371690.
   Google Scholar
• Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol. 2015;62(1398–1404). doi:10.1016/j.jhep.2014.12.034.
   Google Scholar
• Pavlidis P, Powell N, Vincent RP, Ehrlich D, Bjarnason I, Hayee B. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther. 2015;42:802–817. doi:10.1111/apt.13333.
   Google Scholar
• Kanazawa T, Shimazaki A, Sato T, Hoshino T. Syntheses of Ursodesoxycholic Acid and Its Conjugated Bile Acid. Proc Jpn Acad. 1954;30:391–392. doi:10.2183/pjab1945.30.391.
   Google Scholar
• Ikegami T, Matsuzaki Y. Ursodeoxycholic acid: mechanism of action and novel clinical applications. Hepatol Res. 2008;38(123–131). doi:10.1111/j.1872-034X.2007.00297.x.
   Google Scholar
• Fischer S, Müller I, Zündt BZ, Jüngst C, Meyer G, Jüngst D. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur J Gastroenterol Hepatol. 2004;16:305–311. doi:10.1097/00042737-200403000-00010.
   Google Scholar
• Tsubakio K, Kiriyama K, Matsushima N, Taniguchi M, Shizusawa T, Katoh T, Manabe N, Yabu M, Kanayama Y, Himeno S. Autoimmune pancreatitis successfully treated with ursodeoxycholic acid. Intern Med. 2002;41:1142–1146. doi:10.2169/internalmedicine.41.1142.
   Google Scholar
• Sinakos E, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology. 2010;52(197–203). doi:10.1002/hep.23631.
   Google Scholar
• Poupon RE, Bonnand AM, Queneau PE, Trépo C, JPí Z, Vetter D, Raabe JJ, Thieffin G, Larrey D, Grangé JD, et al. Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon. Scand J Gastroenterol. 2000;35:642–649. doi:10.1080/003655200750023624.
   Google Scholar
• Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou JF, Chazouilleres O, Poupon RE, Poupon R. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology. 2003;38(1):203–209. doi:10.1053/jhep.2003.50311.
   Google Scholar
• Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386(1565–1575). doi:10.1016/s0140-6736(15)00154-3.
   Google Scholar
• Zhang L, Liu X-H, Qi H-B, Li Z, Fu X-D, Chen L, Shao Y. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. Eur Rev Med Pharmacol Sci. 2015;19:3770–3776.
   Google Scholar
• Copaci I, Micu L, Iliescu L, Voiculescu M. New therapeutical indications of ursodeoxycholic acid. Rom J Gastroenterol. 2005;14:259–266.
   Google Scholar
• Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BAJ, Schaap FG, Rust C, Beuers U. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol. 2012;57(1):133–140. doi:10.1016/j.jhep.2012.02.014.
   Google Scholar
• Crosignani A, Setchell KD, Invernizzi P, Larghi A, Rodrigues CM, Podda M. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet. 1996;30:333–358. doi:10.2165/00003088-199630050-00002.
   Google Scholar
• Asciutti S, Castellani D, Nardi E, Morelli O, Clementi M, Chistolini F, Gentili G, Setchell KDR, O’Connell N, Pellicciari R, et al. A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon. Anticancer Res. 2009;29:4971–4979.
   Google Scholar
• Ma YQ, Zhang ZZ, Li G, Zhang J, Xiao HY, Li XF. Solidification drug nanosuspensions into nanocrystals by freeze-drying: a case study with ursodeoxycholic acid. Pharm Dev Technol. 2014;1–9. doi:10.3109/10837450.2014.982822.
   Google Scholar
• De AK, Sana S, Datta S, Mukherjee A. Protective efficacy of ursodeoxycholic acid nanoparticles in animal model of inflammatory bowel disease. J Microencapsul. 2014;31(8):725–737. doi:10.3109/02652048.2014.918666.
   Google Scholar
• Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, Pollheimer M, Krones E, Kienbacher C, Traussnigg S, et al. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. Dig Dis. 2015;33(3):433–439. doi:10.1159/000371904.
   Google Scholar
• Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, Durchschein F, Thüringer A, Zollner G, Denk H, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol. 2013;58:1201–1208. doi:10.1016/j.jhep.2013.01.026.
   Google Scholar